NCT Number: NCT02568657
Uterine Tamponade for Treatment of Primary Postpartum Hemorrhage
Postpartum hemorrhage (PPH) is responsible for around 25% of maternal mortality worldwide reaching as high as 60% in some countries.
Postpartum hemorrhage is defined as loss of 500 mL or more in a vaginal delivery and 1 Litre or more in a cesarean delivery.Also any blood loss that cause hemodynamic instability should be considered a PPH.
In 2012, WHO updated the guidelines for the management of PPH and retained placenta to include: "The use of intrauterine balloon tamponade is recommended for the treatment of PPH due to uterine atony. This recommendation is now stronger than the previous guidelines. It can be used for women who do not respond to uterotonics or if uterotonics are not available. This procedure potentially can avoid surgery and is appropriate while awaiting transfer to a higher-level facility".Furthermore, FIGO included Uterine balloon tamponade as a recommended second-line intervention for the treatment of PPH in their updated guidelines issued in 2012.
In 2006, the ACOG Practice Bulletin, published by the American College of Obstetricians and Gynecologists, made mention of the Bakri postpartum balloon for its specifically tailored design that enables conservative management of uterine bleeding in cases of uterine atony and other causes of PPH.
The reports demonstrated that balloon tamponade is helpful in managing PPH secondary to a wide variety of causes in resource-poor settings.
One of the new methods that could be used to control PPH is Uterine packing with chitosan-covered gauze or Celox.
Celox Haemostats are dressings with natural material called chitosan to control major haemorrhage including life-threatening bleeding . They are simple and effective, stopping major bleeding.It was first used by military forces to stop sever bleeding in the scene with no other options to stop bleeding. Celox™ granules are actually very high surface area flakes. When they come in contact with blood, Celox™ swells, gels, and sticks together to make a gel like clot, without generating any heat. Celox™ does not set off the normal clotting cascade, it only clots the blood it comes directly into contact with. Celox works on casualties using anticoagulants and anti-platelet therapy such as aspirin .
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–40 year
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
About this study
Balloon tamponade is helpful in managing PPH secondary to a wide variety of causes in resource-poor settings.
One of the new methods that could be used to control PPH is Uterine packing with chitosan-covered gauze or Celox.
Celox Haemostats are dressings with natural material called chitosan to control major haemorrhage including life-threatening bleeding . They are simple and effective, stopping major bleeding.It was first used by military forces to stop sever bleeding in the scene with no other options to stop bleeding. Celox™ granules are actually very high surface area flakes. When they come in contact with blood, Celox™ swells, gels, and sticks together to make a gel like clot, without generating any heat. Celox™ does not set off the normal clotting cascade, it only clots the blood it comes directly into contact with. Celox works on casualties using anticoagulants and anti-platelet therapy such as aspirin.
We will be having two groups:
- Celox group:
Celox placement is very simpe . During cesarean section celox is loaded in the lower uterine segment and part of it is passed through the cervix to the vagina. If PPH occurs after vaginal delivery the celox is inserted through the cervix to pack the lower uterine segment. Removal of Celox after 24 hours.
- Bakri balloon group:
Before insertion the balloon, ensure that the bladder is empty by placing a Foley catheter. Grasp the cervix with ring forceps. Insert the balloon into the cavity of the uterus under ultrasound guidance; making sure that the entire portion of the balloon passes the cervical canal above the internal cervical os. Once the correct placement is confirmed, inflate the balloon with sterile saline using the enclosed syringe.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Women who accept to participate (either the patient or her first-kin if she is unconscious)
- Primary atonic postpartum hemorrhage
Exclusion criteria
- Traumatic postpartum haemorrhage
Treatment and study plan
Bakri Balloon
DevicePrimary outcomes
-
Amount of blood loss (mL)
Time frame: 8 months
Sponsors and collaborators
Lead sponsor
Assiut University
Other
Registry information
Official study title
Comparison Between Celox Versus Bakri Balloon for Treatment of Primary Atonic Postpartum Hemorrhage
Important dates
- Study start
- 2015
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Oct 6, 2015
- Registry last updated
- Aug 12, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Placental Removal Method And Uterine Massage On Preventing Postpartum Hemorrhage
NCT06192836
Cesarean Section Complications, Dystocia
Ankara, Turkey (Türkiye)
View Trial DetailsPersonalized ViscoElastic Testing-guided Bleeding Management In Liver Surgery, Neurosurgery and Obstetrics
NCT06635564
Bleeding Disorder, Brain Diseases
Vienna, Austria
View Trial DetailsPrevalence of Psychological Disorders After Immediate Postpartum Hemorrhage
NCT03120208
Depression, Postpartum, Depressive Disorder
Clermont-Ferrand, France
View Trial DetailsTiming of Thromboprophylaxis After Postpartum Hemorrhage
NCT07689136
Cardiovascular Diseases, Deep Vein Thrombosis
Tunis, Tunisia
View Trial Details